Organon & Co.
$13.67
$0.01 (+0.07%)
$13.65Day Range$13.68
Key Statistics
Market Cap
$3.59B
Shares Outstanding
262.6M
Primary Exchange
XNYS
Currency
USD
Type
CS
IPO Date
May 14, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$13.65
Day High
$13.68
Day Low
$13.65
Volume
2.07M
VWAP
$13.67
Prev Close
$13.66
Transactions
--
Acc. Volume
--
About Organon & Co.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
PHARMACEUTICAL PREPARATIONSSIC 283410,000 employees30 HUDSON STREET, JERSEY CITY, NJ, 07302551-430-6000IPO May 14, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001821825
- Composite FIGI
- BBG00ZQRGW24
- Share Class FIGI
- BBG00ZQRGW42
- Ticker Root
- OGN
- SIC Code
- 2834
About Organon & Co. (OGN) Stock
Organon & Co. (OGN) closed the 2026-09-16 session at $13.67, up 0.07% versus the previous close (+0.01). The stock opened at $13.65 and traded between $13.65 and $13.68 during that session. Session trading volume was 2.1M shares. The volume-weighted average price (VWAP) is $13.67.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Organon & Co. has a market capitalization of $3.59 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. OGN is listed on the XNYS exchange. The company employs approximately 10,000 people. Organon & Co. is headquartered in JERSEY CITY, NJ. The recorded listing date is 2021-05-14.
On this page you can find market OGN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.